• 东南大学启动基金    2024-2027
• 国家自然科学基金青年科学基金项目  Pygo2在前列腺癌中通过调控干扰素信号通路抑制抗肿瘤免疫的作用与机制研究  2025-2027

·  DongL, Zhu Y, Zhang H, et al. Open-Source Throttling of CD8+ TCells in Brain with Low-Intensity Focused Ultrasound-Guided Sequential Deliveryof CXCL10, IL-2, and aPD-L1 for Glioblastoma Immunotherapy. Adv Mater.Published online September 12, 2024. doi:10.1002/adma.202407235

·  MurphyS, Rahmy S, Gan D, Liu G, Zhu Y, Manyak M, Duong L, He J, Schofield JH,Schafer ZT, Li J, Lu X, Lu X. Ketogenic diet alters the epigenetic and immunelandscape of prostate cancer to overcome resistance to immune checkpointblockade therapy. Cancer Res. 2024 Apr 8. doi: 10.1158/0008-5472.CAN-23-2742. 

·  GanD, Zhu Y, Lu X, Li J. SCIPAC: quantitative estimation of cell-phenotypeassociations. Genome Biol. 2024;25(1):119. Published 2024 May 13.doi:10.1186/s13059-024-03263-1 

·  ZhuY, Zhao Y, Wen J, Liu S, Huang T, HatialI, Kao KR, Maeda DY, Dai X, Wiest O, Blagg BSJ, Lu X, Cheng L, Wan J, Lu X.Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses andovercomes immunotherapy resistance in prostate cancer. Sci Immunol. 2023Mar 17;8(81):eade4656. doi: 10.1126/sciimmunol.ade4656. 

·  ZhangY; Kim G; Zhu Y;  Wang C; Zhu R;Lu X; Chang HC; Wang Y. Chiral Graphene Quantum Dots Enhanced Drug Loading intoSmall Extracellular Vesicles. ACS Nano, 2023, https://doi.org/10.1021/acsnano.3c00305,  

·  Zhao Y,Liu Z, Liu G, Zhang Y, Liu S, Gan D, Chang W, Peng X, Sung ES, Gilbert K, ZhuY, Wang X, Zeng Z, Baldwin H, Ren G, Weaver J, Huron A, Mayberry T, Wang Q,Wang Y, Diaz-Rubio ME, Su X, Stack MS, Zhang S, Lu X, Sheldon RD, Li J, ZhangC, Wan J, Lu X. Neutrophils resist ferroptosis and promote breast cancermetastasis through aconitate decarboxylase 1. Cell Metab. 2023 Oct3;35(10):1688-1703.e10. doi: 10.1016/j.cmet.2023.09.004. 

·   ·  ZhangC, Huo X, Zhu Y, Higginbotham JN, Cao Z, Lu X, Franklin JL, Vickers KC,Coffey RJ, Senapati S, Wang C, Chang HC. Electrodeposited magnetic nanoporousmembrane for high-yield and high-throughput immunocapture of extracellularvesicles and lipoproteins. Commun Biol. 2022 Dec 10;5(1):1358. doi:10.1038/s42003-022-04321-9. 

·  ZhuY, Duong L, Lu X, Lu X.Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape ofprostate cancer. Asian J Androl. 2022 Nov 8. doi: 10.4103/aja202283.Epub ahead of print. PMID: 36367020. 

·  ZhuY, Wen J, Huang G, Mittlesteadt J, Wen X,Lu X. CHD1 and SPOP synergistically protect prostate epithelial cells from DNAdamage. Prostate. 2021 Jan;81(1):81-88. doi: 10.1002/pros.24080. Epub 2020 Oct6. PMID: 33022763.

·  WeiB*, Zhu Y*, Yang P, Han Y, Wang S, Wang X, Xia S, Song X, Zhang Z, WangS, Rondard P, Pin JP, Jiang X, Liu J. GABAB1e promotes the malignancy of humancancer cells by targeting the tyrosine phosphatase PTPN12. iScience. 2021 PMID:34778730; PMCID: PMC8577127. Co-first Author 

·  WenJ, Huang G, Liu S, Wan J, Wang X, Zhu Y, Kaliney W, Zhang C, Cheng L,Wen X, Lu X. Polymorphonuclear MDSCs are enriched in the stroma and expanded inmetastases of prostate cancer. J Pathol Clin Res. 2020 Jul;6(3):171-177. PMID:32149481; PMCID: PMC7339199. 

Xia S, He C, Zhu Y,Wang S, Li H, Zhang Z, Jiang X, Liu J. GABABR-Induced EGFR TransactivationPromotes Migration of Human Prostate Cancer Cells. Mol Pharmacol. 2017Sep;92(3):265-277. doi: 10.1124/mol.116.107854. Epub 2017 Apr 19. PMID:28424220.